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AbstrAct
Protein Tyrosine Phosphatase, Receptor Type G (PTPRG) was identified as a 
candidate tumor suppressor gene in nasopharyngeal carcinoma (NPC). PTPRG 
induces significant in vivo tumor suppression in NPC. We identified EGFR as a PTPRG 
potential interacting partner and examined this interaction. Dephosphorylation of 
EGFR at EGFR-Y1068 and -Y1086 sites inactivated the PI3K/Akt signaling cascade 
and subsequent down-regulation of downstream pro-angiogenic and -invasive 
proteins (VEGF, IL6, and IL8) and suppressed tumor cell proliferation, angiogenesis, 
and invasion. The effect of Akt inhibition in NPC cells was further validated by Akt 
knockdown experiments in the PTPRG-down-regulated NPC cell lines. Our results 
suggested that inhibition of Akt in NPC cells induces tumor suppression at both the 
in vitro and in vivo levels, and also importantly, in vivo metastasis. In conclusion, 
we confirmed the vital role of PTPRG in inhibiting Akt signaling with the resultant 
suppression of in vivo tumorigenesis and metastasis.
IntroductIon
The incidence of nasopharyngeal carcinoma (NPC) 
is highest in Southeast China and Asia. Epstein-Barr Virus 
(EBV) infection was found to closely associate with NPC 
development. EBV infection in the epithelial cells was 
reported to be crucial to induce host cell signaling changes 
during cancer progression. The EBV oncogenic latent 
gene, Latent Membrane Protein 1 (LMP1), can activate 
various signaling pathways, including the PI3K/Akt 
signaling pathway, and results in enhancing cell survival 
[1]. Furthermore, LMP1 up-regulates [2] and activates 
EGFR in NPC cells [3]. A positive correlation between 
the phosphorylated-EGFR and phosphorylated-Akt was 
detected in NPC patient tumors, suggesting a regulatory 
role of EGFR in Akt activation in NPC [4]. Inhibition of 
the EGFR by EGFR-specific tyrosine kinase inhibitors 
significantly suppressed NPC cell growth [5]. These 
previous studies suggested the importance of the EGFR/
PI3K/Akt signaling in NPC.
Our previous NPC study identified a candidate 
tumor suppressor gene (TSG), Protein Tyrosine 
Phosphatase, Receptor Type G (PTPRG), which belongs 
to the tyrosine phosphatase (PTP) family. PTP family 
members are associated with cancer development and 
they function in an opposite manner to receptor tyrosine 
kinases (RTKs), which mainly participate in regulation of 
various crucial signaling pathways to control cell cycle 
progression, proliferation, invasion, and angiogenesis. The 
balances between the activities of PTP and RTK members 
are vital to maintain cell signaling homeostasis. Imbalance 
between the activities of PTPs and RTKs is critical for 
inducing malignant transformation of normal cells [6]. The 
classical PTPs are categorized into receptor, non-receptor, 
and also dual specificity phosphatase (DUSP) types [7]. 
Members in the PTP super family can be either oncogenic 
or tumor suppressive. The functional roles of PTPs are 
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mainly determined by their subcellular localization and 
also their interacting partners. 
Recently, various members in the receptor type 
PTP family were identified as tumor suppressors. Among 
them, PTEN is one of the best-studied members. PTEN 
can induce dephosphorylation of PI3K and inactivation 
of the PI3K/Akt signaling pathway activities. The PI3K/
Akt pathway plays a major role in control of cell growth, 
proliferation, cell survival, angiogenesis, and invasion 
[7]. Mutations resulting in its deregulation are commonly 
observed in various cancers, including NPC. 
In this current study, the tumor suppressive role 
of PTPRG was investigated. PTPRG point mutations 
have been identified in colon cancer patients [8]. Down-
regulation and promoter hypermethylation are critical 
factors associated with PTPRG inactivation in cancer 
and have been observed in sporadic and Lynch syndrome 
colorectal cancer [9], ovarian, breast, and lung cancers 
[10], gastric cancer [11], chronic myeloid leukemia 
[12], T-cell lymphoma [13], and NPC [14]. Functional 
studies suggested that re-expression of PTPRG induced 
significant tumor suppressive effects in different cancers. 
Over-expression of PTPRG in breast cancer cells prolongs 
doubling times and colony sizes of breast cancer cells [15] 
and inhibits in vivo breast tumor formation through up-
regulation of p21 and p27 by suppression of ERK1/2 [16]. 
PTPRG interacts and dephosphorylates the oncogenic 
fusion protein, BCR/ABL, to inactivate its downstream 
signaling molecules [12]. Our earlier NPC study also 
confirmed that re-expression of PTPRG suppressed in 
vivo tumor growth and induced cell cycle G0/G1 arrest 
by down-regulation of cyclin D1 protein levels and, 
thus, reduced phosphorylation of pRB [14]. However, 
the PTPRG-associated signaling changes remain unclear. 
Further studies are necessary to identify the role of this 
PTP in cancer development.
In this current study, we identified the potential 
PTPRG-associated signaling pathways and protein-
interacting partners that impact its tumor and metastasis 
suppressive roles in NPC.
results
PtPrG reduces phosphorylation of the Akt 
signaling pathway cascade in nPcs
Previous studies showed PTPRG is involved in 
regulation of the ERK1/2 signaling pathway in breast 
cancer cells [16] and also cyclinD1/Rb in NPC [14]. In 
order to identify PTPRG-regulated targets in NPC, a 
human kinase phosphorylation-specific antibody array 
was utilized to examine the changes in phosphorylation 
levels of protein kinases after re-expressing PTPRG in 
NPC cells. A tumor-suppressive PTPRG-expressing clone 
and vector-alone (VA), which were previously established 
in the HONE1 NPC cell line [14] engineered with a 
tetracycline-regulated inducible (tet-off) system [17], were 
used for this antibody array study. Several changes were 
observed in the antibody array assay. In this current study, 
we focused on the changes of phosphorylation levels of 
Akt and its downstream molecules, as shown in Figure 
1A and Supplementary Table 1. After hybridization of the 
protein lysates of VA and PTPRG-expressing clones to 
the antibody array, dramatic reduction of phosphorylation 
of p38α-T180/Y182, CREB-S133, JNK-T183/185, 
T221/223, Akt-S473 and -T308, and c-jun-S63, was 
detected (Figure 1A and 1B), providing evidence to 
support a role for PTPRG as an Akt signaling regulator 
in cancer. 
PtPrG co-immunoprecipitates with eGFr
PTPRG is classified as a membrane receptor [18]. 
The phosphorylation antibody array data indicated that 
re-expression of PTPRG reduced the phosphorylation 
not only at the tyrosine site of Akt, but also at both the 
Akt-S473 and -T308 phosphorylation sites (Figure 1A and 
1B). As PTPRG is a tyrosine phosphatase, this suggested 
that PTPRG might not function alone to directly reduce 
Akt phosphorylation. Therefore, determining how 
PTPRG regulates the phosphorylation of the Akt signaling 
members was further investigated. We, thus, performed 
co-immunoprecipitation (CoIP) to identify PTPRG 
protein-interacting partner(s). CoIP results suggested that 
PTPRG directly interacts with a cell surface receptor, 
EGFR, which is one of the key cell surface receptors to 
activate the Akt signaling pathway (Figure 2A). Thus, 
EGFR is one of the potential PTPRG targets suppressing 
Akt signaling pathway phosphorylation.
PtPrG reduces eGFr phosphorylation levels 
and regulates downstream PI3K/Akt and p38
EGFR phosphorylation was confirmed to induce Akt 
phosphorylation in NPC [4]. Taken together with the CoIP 
results, we investigated the role of PTPRG in regulating 
the EGFR/Akt signaling phosphorylation in NPC. In our 
previous NPC study, PTPRG was confirmed to be down-
regulated in the NPC cell lines, including HONE1 and 
HK1 [14]. Therefore, these two NPC cell lines were used 
in these current studies. In the previously established 
HONE1-PTPRG inducible clone, in the absence of 
doxycycline (-Dox), PTPRG protein is expressed. In the 
presence of Dox (+Dox), PTPRG expression levels are 
down-regulated (Figure 2B). In the HK1 cell line, PTPRG 
was transiently expressed (Figure 2B).
This panel of PTPRG-expressing NPC cell lines 
was used to investigate the contribution of PTPRG 
in regulating the phosphorylation of EGFR and Akt 
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signaling members. Phosphorylation levels of the two 
EGFR tyrosine sites, Y1068 and Y1086, were reduced in 
the PTPRG-expressing HONE1 and HK1 cells (Figure 
2B). These two phosphorylation sites are responsible 
for EGFR-associated PI3K/Akt and MAPK signaling 
activation. Based on these results, phosphorylation levels 
of their expected downstream signaling targets were also 
investigated by Western blot (WB) analysis. Reduction 
of phosphorylation of EGFR downstream signaling 
molecules, including p-Gab1 (Y627 and Y307), PI3K/p-85 
(Y458), p-PDK1 (S241), and Akt (S473 and T308) was 
observed in the PTPRG-expressing cells (Figure 2B). This 
suggested the ability of PTPRG to regulate Akt signaling 
through dephosphorylation of EGFR. 
To further confirm the ability of PTPRG to 
regulate the Akt signaling, phosphorylation levels of 
Akt downstream targets, including p-JNK, p-c-jun, and 
p-CREB were investigated. Results suggested that their 
phosphorylation was greatly reduced when PTPRG was 
expressed (Figure 2C). Furthermore, one of the MAPK 
signaling members, p38, which also showed decreased 
phosphorylation levels in the PTPRG phosphorylation 
antibody array, showed a lower phosphorylation level after 
PTPRG expression (Figure 2C). This further confirmed the 
ability of PTPRG to regulate the phosphorylation of the 
EGFR to suppress the downstream signaling pathway.
Akt inhibition in the PtPrG-down-regulated 
nPc cells induces in vivo tumor suppression
Akt signaling is a key signaling pathway for cancer 
development. Our results show that PTPRG can reduce the 
phosphorylation of members of the Akt signaling pathway. 
In order to further confirm the role of Akt inhibition in 
tumor suppression in NPC cells, Akt inhibition in the 
two NPC tumorigenic PTPRG-down-regulated cell 
lines, HONE1 and HK1, was further investigated. A 
commercially available Akt-specific inhibitor, Akt XIII, 
Figure 1: Protein kinase phosphorylation levels associated with PtPrG expression. A. Changes of phosphorylation levels of 
Akt and its downstream molecules observed on the phosphorylation array of the vector-alone (VA) and PTPRG-expressing clones. Duplicate 
spots: 1) p38α (T180/Y182), 2) CREB (S133), 3) JNK (T183/Y185, T221/Y223), 4) Akt (S473), 5) Akt (T308), and 6) c-jun (S63). b. 
Relative phosphorylation levels of protein kinases differentially expressed in the PTPRG-expressing clones. Relative phosphorylation 
levels were calculated by comparing the intensity seen on the protein array of the PTPRG-expressing clones versus VA controls.
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was first utilized to inhibit the Akt activity in these two 
cell lines. After treating the HONE1 and HK1 cells with 
different concentrations of Akt inhibitor (DMSO control, 
1.25 µM, 2.5 µM, 5 µM, and 10 µM), significant in vitro 
suppression of cell proliferation is observed (Figure 
3A). The inhibitory effects increased with the increased 
concentrations of the Akt inhibitor (Figure 3A). Results 
suggested Akt inhibition plays a significant role in 
suppressing NPC cell growth. 
In order to perform a more specific Akt inhibition 
experiment, Akt shRNA knockdowns were used 
for both HONE1 and HK1 cell lines to functionally 
evaluate the specific effect of inactivating the Akt 
signaling pathway in NPC cell lines. Akt knockdown 
experiments were performed using two sets of knockdown 
oligonucleotides (AKT984 and AKT1793) and the 
scramble oligonucleotides served as knockdown controls. 
Both sets of knockdown oligonucleotides showed a high 
efficiency for Akt knockdown in the two tested NPC cell 
lines (Figure 3B). 
By using the panel of Akt knockdown 
oligonucleotides and the control, our results suggested 
that inhibition of Akt suppressed in vitro cell proliferation 
in both PTPRG-down-regulated HONE1 and HK1 cells 
(Figure 3C). The proliferation rate in HONE1 decreased 
from 100% with the scramble oligonucleotides (Ctrl) to 
39.8% using the AKT984 knockdown oligonucleotide 
and 6.7% with the AKT1793 oligonucleotide. The same 
Figure 2: PtPrG interacts with eGFr and regulates the eGFr/PI3K/Akt signaling pathway. A. CoIP assay was 
performed by utilizing the antibodies to PTPRG and EGFR. The IgG was used as a negative control. PTPRG showed interaction with the 
EGFR. b. Re-expression of PTPRG reduced phosphorylation of EGF/PI3K/AKT signaling pathway members (EGFR, Gab1, PI3K/p85, 
PDK1, and AKT) in both PTPRG-re-expressing HONE1 and HK1 NPC cell lines. The α-tubulin served as an internal loading control. c. 
PTPRG induced dephosphorylation of Akt downstream signaling molecules. PTPRG reduced the phosphorylation of AKT-downstream 
signaling members (JNK, c-jun, and CREB) and MAPK-downstream signaling member, p38, in both HONE1 and HK1. The α-tubulin 
served as an internal loading control.
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proliferation inhibition is also observed with the HK1 cell 
line; the proliferation rate decreased from 100% in the Ctrl 
to 71.4% with the AKT984 oligonucleotide and 67.8% 
with the AKT1793 oligonucleotide (Figure 3C). This 
demonstrates the inhibitory effect on cell proliferation by 
Akt inhibition in NPC. 
In order to obtain functional evidence to support 
the suppressive role of PTPRG-associated Akt inhibition 
in vivo, the effects of Akt inhibition on the in vivo 
tumor growth were investigated using a nude mouse 
tumorigenicity assay. Knockdown of Akt in both 
HONE1 and HK1 cells induced significant in vivo tumor 
suppression, when compared to the control groups (p 
< 0.05) (Figure 3D). These results suggested that Akt 
knockdown reduces in vivo tumorigenicity and confirmed 
the important functional role of Akt inhibition on tumor 
suppression. The results also validated the role of PTPRG 
in tumor suppression [14] through inhibition of Akt 
signaling. 
PtPrG inhibits invasion and angiogenesis via Akt 
inhibition
Activation of invasion and angiogenesis are key 
hallmarks of cancer development [19]. As Akt signaling 
pathways can regulate invasion and angiogenesis 
processes, therefore, the regulatory roles of PTPRG in 
NPC invasion and angiogenesis were investigated.
Results suggested that PTPRG was able to inhibit 
in vitro tumor invasion. Significant reduction of invasive 
abilities in the PTPRG-expressing HONE1 cells (34.3%) 
was observed, when compared to the VA control (+Dox; 
100% and 78%, respectively), as well as when the 
Figure 3: targeting Akt inhibited in vitro cell proliferation and in vivo tumor formation. A. In vitro cell proliferation assay 
of the HONE1 and HK1 treated with Akt inhibitor. Different concentrations of the Akt inhibitor (1.25 µM, 2.5 µM, 5 µM, and 10 M) and 
DMSO control were used for the treatment of the two NPC cell lines. The relative proliferation rate was compared to the DMSO control. 
Data are represented as the mean + SD. b. Akt protein levels in the HONE1 and HK1 cells after Akt knockdown. The scramble control 
(Ctrl) and two sets of Akt knockdown oligonucleotides, AKT984 and AKT1793, were used in the knockdown experiments. c. In vitro cell 
proliferation assay of HONE1 and HK1 after Akt knockdown. The relative proliferation rate was compared to the scramble control (Ctrl). 
Data are represented as mean + SD. d. In vivo tumorigenicity assay of HONE1 and HK1 after Akt knockdown. The curves represent an 
average tumor volume of all six injection sites. Data are represented as mean + SEM. The Ctrl formed large tumors and the Akt knockdown 
resulted in reduced tumor sizes. 
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PTPRG expression was switched off in the presence of 
doxycycline (+Dox; 73.6%) (Figure 4A). The invasion 
inhibitory effect was further confirmed in HK1; re-
expression of PTPRG reduced invasion to 67.3%, when 
compared to the VA control (Figure 4A). The role of Akt 
inhibition on invasion suppression of cancer cells was 
also investigated; significant suppression of invasion was 
observed with both HONE1 and HK1 cell lines expressing 
both Akt knockdown oligonucleotides (32.9% and 22.74% 
for AKT984 and AKT1793 in HONE1, respectively, and 
58.5% and 60.7% for AKT984 and AKT1793 in HK1, 
respectively) (Figure 4B). This suggested that targeting 
Akt via PTPRG could induce invasion suppression.
In addition to invasion suppression, Akt plays 
an important role in activating angiogenesis. The 
functional role for PTPRG regulation of angiogenesis was 
investigated by the HUVEC tube formation assay. Re-
expression of PTPRG in both HONE1 and HK1 cell lines 
suppressed HUVEC tube-forming abilities (Figure 4C). 
Significant reduction of tube formation in the PTPRG-
expressing HONE1 cells (57.8%) can be observed, when 
compared to the VA control (+Dox; 100% and 90.0%, 
respectively) and also when the PTPRG expression 
was switched off (+Dox; 82.4%). In HK1 cell lines, re-
expression of PTPRG also inhibits tube formation. The 
HUVEC tube formation ability was reduced to 28.4% for 
PTPRG-expressing cells. 
Targeting Akt in the PTPRG-down-regulated NPC 
cells also inhibited HUVEC tube formation (Figure 4D). 
Significant tube formation suppression was observed in 
both HONE1 and HK1 cell lines expressing both Akt 
knockdown oligonucleotides (69.8% and 76.1% for 
AKT984 and AKT1793 in HONE1, and 56.2% and 85.2% 
for AKT984 and AKT1793 in HK1, respectively). These 
results indicate that regulation of the Akt signaling by 
PTPRG is associated with anti-angiogenesis.
Figure 4: re-expression of PtPrG and targeting Akt suppressed angiogenesis and invasion. A. Re-expression of PTPRG in 
cancer cell lines, HONE1 and HK1, induced inhibition of invasion. For HONE1, the relative invasion ability was compared to the VA in the 
presence of Doxycycline (+Dox), and for HK1, the relative invasion ability was compared to the VA control. b. Akt knockdown inhibited 
the invasion ability of HONE1 and HK1. The relative invasion ability was compared to the scramble control (Ctrl). c. Re-expression of 
PTPRG reduced the tube-forming ability of HUVEC. For the CM from HONE1, the relative tube-forming ability was compared to the VA 
(+Dox), and for the CM from HK1, the relative invasion ability was compared to the VA control. d. Akt knockdown inhibited the tube-
forming ability of HUVEC. The relative tube-forming ability was compared to the scramble control (Ctrl). * and **, p < 0.05, statistically 
significant differences compared with the VA and corresponding with dox control, respectively. Data are represented as mean + SD. 
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PTPRG suppression of invasion and angiogenesis 
was further confirmed by measuring the expression of Akt 
downstream signaling molecules. The suppressive effects 
can contribute to down-regulation of Akt downstream pro-
invasion and pro-angiogenesis factors, including IL6, IL8, 
and VEGF (165 and 189). These genes showed a trend of 
down-regulation in the PTPRG-expressing clones (Figure 
5A) and in the Akt knockdown HONE1 and HK1 cells 
(Figure 5B). The protein secretion levels of the invasion- 
and angiogenesis-regulator, VEGF, in the conditioned 
media (CM) of the HONE1 and HK1 cells were confirmed 
by ELISA. Re-expression of PTPRG and Akt knockdown 
induced significant reduction of VEGF protein secretion 
in the CM (Figure 5C and 5D). Significant reduction of 
VEGF secretion in the PTPRG-expressing HONE1 cells 
to a level of 22.5% was observed, when compared to 
the VA control (+Dox), with levels of 100% and 68.2%, 
respectively, and also when the PTPRG expression was 
switched off (+Dox; 84.2%) (Figure 5C). Re-expression 
of PTPRG in the HK1 cell line reduced the secretion 
of VEGF to 64.5%. Targeting Akt also induced down-
regulation of VEGF secretion in both HONE1 and HK1 
cell lines. The secretion of VEGF was reduced to 69.8% 
and 76.1% for AKT984 and AKT1793 knockdowns in 
HONE1, respectively, and 56.2% and 85.2% for AKT984 
and AKT1793 in HK1, respectively. This is consistent 
with the functional assay results showing PTPRG 
inhibits invasion and angiogenesis of the cancer cells 
and associates with the regulation of the Akt signaling 
pathway. 
Figure 5: re-expression of PtPrG and targeting Akt induced down-regulation of the Akt downstream post-angiogenic 
and invasion molecules. A. QPCR results of PTPRG-expressing clones. Re-expression of PTPRG down-regulated the IL6, IL8, 
VEGF165, and VEGF189 in both HONE1 and HK1. b. QPCR results of the HONE1 and HK1 after Akt knockdown. Knockdown of Akt 
down-regulated IL6, IL8, VEGF165, and VEGF189 in both HONE1 and HK1. c. VEGF ELISA assay performed with CM of PTPRG-
expressing clones. Re-expression of PTPRG reduced the secretion of VEGF protein in the CM. For HONE1 and HK1, the relative VEGF 
levels were compared to the VA (+Dox) controls. Data are represented as mean + SD. d. VEGF ELISA assay performed with CM of 
HONE1 and HK1 after Akt knockdown. Knockdown of Akt reduced the secretion of the VEGF in the CM. The relative VEGF levels were 
compared to the scramble control (Ctr). * and **, p < 0.05, statistically significant differences compared with the VA and corresponding 
with dox control, respectively. Data are represented as mean + SD.
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Knockdown of Akt in nPc cells suppresses in vivo 
invasion
To further evaluate the contribution of targeting 
the Akt signaling in in vivo metastasis, a luciferase-
labelled metastatic NPC cell line, HONE1, was used for 
intrasplenic injection in nude mice. The in vivo metastasis 
of the scramble control and the Akt knockdown clones was 
monitored by the Xenogen live imaging system (Figure 
6A). The HONE1 cell line showed a high metastasis rate 
to the liver region. Visible tumor nodules (Figure 6B) 
were observed in 77% of livers in the control group. A 
statistically significant metastatic inhibition (p = 0.047) 
was observed for the AKT knockdown groups (41%) 
versus the Ctrl group (Figure 6Ci). A trend of decreased 
metastasis to 27% and 57% was observed in the two Akt 
knockdown clones, AKT984 and AKT1793, respectively, 
when compared to the Ctrl group (Figure 6Cii). The 
results were further validated by H&E staining (Figure 
6D); representative H&E staining images of liver tumor 
nodules (Figure 6Di and 6Dii) and metastasis-negative 
samples (Figure 6Diii and 6Div) are shown. These results 
provide evidence for the functional role of Akt inhibition 
in suppression of in vivo metastasis. 
Figure 6: In vivo metastasis assay of cancer cells after Akt knockdown in mice by intrasplenic injection. A. Representative 
images of the in vivo animal imaging system of the scramble control (Ctrl), and AKT984 and AKT1793 knockdown constructs. 
Representative images for the metastasis are observed with the scramble control group. The bioluminescence signals indicated the location 
of the cancer cells. b. Mice after the bioluminescence signal detection were sacrificed and dissected. The livers were excised and the 
presence of metastasis was investigated by histology. Lesions in the livers were observed in the liver if metastasis occurred. Representative 
images of lesions in the livers are indicated by a white arrow. c. Summary of the liver metastasis ability of the cancer cells. High percentage 
of metastasis of the cancer cells was observed in the scramble control (Ctrl), while the Akt knockdown constructs (AKT984 and AKT1793) 
showed a relatively low trend of metastasis. Comparison of the metastatic rate of the Ctrl to a (i) combination of the two knockdown 
groups (p = 0.047) and (ii) two individual knockdown groups. d. Histological analysis of the livers from the experimental mice to confirm 
the existence of tumor cells in the mouse livers. Representative H&E staining images of liver tissues from the Ctrl and Akt knockdown 
constructs. (i and ii) Livers from the scramble group (Ctrl), which were identified in mice with metastases using different magnifications 
(1X and 10X). (iii and iv) Livers from the AKT knockdown groups (AKT984 and AKT1793) were identified in mice with no observable 
metastasis.
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dIscussIon
Clarification of the molecular mechanisms for NPC 
development is still unclear and oncogenic changes in 
different signaling pathways occurring during malignant 
transformation need further study. In this current study we 
demonstrate the functional role of a previously identified 
gene of interest in NPC, PTPRG, which belongs to the 
PTP family. Ongoing research of PTP family members 
suggests their importance in modulating cellular signaling 
pathways, which are associated with cancer development. 
A recent head and neck cancer study confirmed that 
mutation of PTPRT results in increased phosphor-STAT3 
levels in the head and neck squamous cell carcinoma 
tumors [20]. Our gene of interest, PTPRG, was previously 
identified as an important tumor suppressor in NPC. 
However, its function in NPC was still unclear; since 
little is known about its protein interacting partners and 
role in regulating cellular signaling pathways. Here, we 
provide evidence to support the regulatory role of this PTP 
in orchestrating the deregulated oncogenic Akt signaling 
pathway in NPC cancer cells. 
Our results confirm the interaction of PTPRG 
and EGFR, and the ability of PTPRG to reduce EGFR 
phosphorylation in NPC. Interestingly, besides PTPRG, 
other PTP family members, PTPRS [21] and PTP1B 
[22], also play critical roles in dephosphorylation 
and inactivation of EGFR. EGFR is a member of the 
RTK family and it is one of the important cancer-
related signaling regulators. EGFR contains several 
phosphorylation sites. After dimerization and binding 
of ligands, including the EGF and TGF-α [23], some 
phosphorylation sites initiate self-phosphorylation and 
activate EGFR function [24]. These phosphorylated sites 
then serve as a docking bay for recruitment and activation 
of downstream signaling molecules. Deregulation of the 
EGFR phosphorylation contributes to cancer. Previous 
study suggested that inhibition of EGFR-Y1068 and 
-Y1086 auto-phosphorylation resulted in attenuation of 
the cancer cell transformed phenotype [25]. EGFR-Y1068 
was shown to be an important binding site for a growth 
receptor binding protein Grb2 [26] and scaffold protein 
Gab1 to activate PI3K/Akt [27] and MAPK [28] signaling 
molecules. The activation of PI3K/Akt is negatively 
regulated by a well-studied tumor suppressor PTEN 
in the PTPase family and results in tumor suppression 
[7]. Interestingly, a previous study of PTPRG in breast 
cancer also confirmed that PTPRG regulates the ERK1/2 
pathway [16], which is also one of the key EGFR-
regulated signaling pathways. Furthermore, a recent 
study in leukocytes also validated the role of PTPRG 
in dephosphorylation of EGFR-Y1068 [30]. These 
results further illustrate the important functional role of 
PTPRG in regulating the EGFR phosphorylation and, 
thus, modulating its downstream Akt and ERK signaling 
pathways.
Clinically, up-regulation of EGFR can be detected 
in NPC patient biopsies [31], as PTPRG can induce 
dephosphorylation of EGFR and, thus, the downstream 
PI3K/Akt signaling pathway; this further supports the 
critical tumor suppressive role of PTPRG in NPC. It is 
well-known that Akt is a central signaling molecule 
modulating many cellular processes and its deregulation 
is crucial for activation of tumorigenic characteristics 
including uncontrolled cell proliferation, angiogenesis, 
invasion, and metastasis. Previous studies indicated 
deregulation of Akt signaling in NPC [1]. Akt helps 
to maintain the cyclin D1 levels via activation of 
transcription factor Ap1 (c-jun/c-fos) [32] and inhibition 
of ubiquitin-mediated cyclin D1 degradation [22, 33]. This 
is consistent with our previous finding that PTPRG re-
expression induced cell cycle G0/G1 arrest in NPC [14] via 
down-regulation of cyclin D1 protein and, thus, reduced 
pRB phosphorylation [14]. The effects of Akt inhibition 
were further validated by Akt knockdown in the PTPRG-
down-regulated NPC cell lines [14]. These experiments 
provide direct evidence to support the functional effects of 
Akt inactivation in cancer and support our finding showing 
that PTPRG re-expression inhibits cell proliferation and in 
vivo tumor growth via Akt inhibition.
PTPRG also plays an anti-angiogenesis role in NPC 
through regulating the expression of EGFR/Akt signaling 
downstream molecules, VEGF, IL6, and IL8. VEGF is one 
of the key pro-angiogenic proteins. In NPC, the oncogenic 
role of VEGF was confirmed; elevated VEGF expression 
is associated with poor overall survival in NPC patients 
[34]. Inhibition of the Akt by PI3K siRNA knockdowns 
induced VEGF protein down-regulation [35, 36] and 
inhibition of angiogenesis. Apart from VEGF, Akt also 
controlled the expression of the pro-angiogenesis proteins 
IL6 and IL8 [37], which are also are involved in regulation 
of angiogenesis in NPC [38]. Re-expression of PTPRG 
suppresses EGFR/Akt signaling activities and induces 
down-regulation of the pro-angiogenic proteins, VEGF, 
IL6, and IL8. This further supports the important function 
of PTPRG in regulating a hallmark of cancer, namely 
angiogenesis, in NPC through Akt signaling inhibition.
In addition to promotion of angiogenesis, pro-
angiogenic proteins, VEGF, IL6, and IL8, can also 
initiate tumor invasion and metastasis. Intense staining of 
VEGF protein is observed in the advanced squamous cell 
carcinoma tissues [39] and is positively correlated with 
invasion and metastasis [40]. High expression of VEGF 
in pancreatic adenocarcinoma samples associates with 
liver metastasis [41]. Increasing evidence supports the 
involvement of both IL6 and IL8 in inducing metastasis 
in cancer. IL6 was confirmed to promote head and neck 
tumor metastasis [42]. The serum IL6 and IL8 levels 
were significantly increased in the colorectal cancer 
patients with liver metastasis [43]. A previous study 
also suggests that suppression of the PI3K/Akt signaling 
results in reducing metastasis in NPC [44]. These findings 
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further validate the role of PTPRG in suppressing tumor 
invasion and metastasis via inhibition of Akt signaling 
and downstream VEGF, IL6, and IL8 and, thus, inhibiting 
tumor invasion and liver metastasis in NPC, as identified 
in this current study.
Several lines of evidence emphasize that inhibition 
of the Akt signaling suppresses the cell proliferation, 
angiogenesis, invasion, and most importantly, metastasis. 
We confirm the vital role of PTPRG in dephosphorylation 
and inactivation of EGFR/Akt signaling and, in turn, the 
downstream Akt signaling pathway cascade to promote 
oncogenesis and NPC development.
MAterIAls And Methods
cell culture
NPC cell lines, HONE1 and HK1, were used in 
this current study. The tetracycline transactivator tTA-
producing PTPRG-expressing HONE1 clone and vector-
alone (VA) were cultured as previously described [14, 17]. 
The HK1 was cultured as previously described [45]. The 
metastatic HONE1 cell line was labeled with luciferase 
markers as described [46] for the in vivo imaging to 
monitor metastasis. All cell lines used in this current 
study were obtained from the Hong Kong NPC AoE 
Cell Line Repository and have been authenticated using 
the AmpFlSTR Identifier PCR Amplification kit (Life 
Technologies).
Phosphorylation antibody array
A human phosphokinase antibody array (R&D 
Systems) was utilized in this current study. The cell culture, 
protein preparation, hybridization, and signal detection 
were performed as described by the manufacturer. The 
intensity of the signals was quantified by the BioRad 
Quantity ONE software using the Molecular Imager Doc 
XR System (BioRad Laboratories) as previously described 
[47]. The vector-alone (VA) and PTPRG-expressing 
clones were used for the phosphorylation array analysis.
co-immunoprecipitation (coIP)
The CoIP experiment was performed as previously 
described [38]. In brief, cells were seeded on 150 mm 
culture plates for 48 hours to obtain sufficient input 
material for the CoIP reaction. The non-denaturing lysis 
buffer was used for protein extraction. The cell lysate was 
then immunoprecipitated with antibodies specific to EGFR 
and PTPRG (Supplementary Table 2) and IgG served as 
a control
Western blot analysis
For the molecular signaling study, the cells were 
seeded onto the cell culture plate to obtain cell lysates for 
the WB analysis. For the inducible clones, the doxycycline 
was removed 16 hours after cell seeding and the cells then 
cultured in the media without doxycycline for 24 hours. 
For the other cell lines, the cells were seeded onto culture 
plates for 24 hours for cell lysate collection. The cell 
lysate was collected and WB analysis was performed as 
previously described [14]. The information on antibodies 
used in this current study is summarized in Supplementary 
Table 2.
AKt1 knockdown construct and AKt inhibitor
The pLKO TRC cloning vector (Addgene no. 
10878) mammalian expression lentiviral plasmid 
was used for the Akt knockdown experiment. The 
knockdown constructs were designed according to 
the instructions of the Public TRC portal. Two sets of 
knockdown oligonucleotides, which targeted Akt, Akt984 
(5’-CCGGCGCGTGACCATGAACGAGTTTCTGCAG 
AAACTCGTTCATGGTCACGCGTTTTTG-3’) 
and Akt1793 
(5’-CCGGGCAGCACGTGTACGAGAAGAACTGCAG 
TTCTTCTCGTACACGTGCTGCTTTTTG-3’), were 
used for the knockdown experiment. The scramble vector 
(Addgene 1864) served as a control. The AKT inhibitor 
XIII (Calbiochem) was used in this study. Cells were 
treated with the inhibitor for 48 hours and then the cell 
proliferation rate was investigated.
In vivo nude mouse tumorigenicity and metastasis 
assays
All in vivo study protocols in this current study were 
approved by the Committee on the Use of Live Animals 
in Teaching and Research, The University of Hong 
Kong and the Department of Health, Hong Kong SAR. 
All mice were kept in the Laboratory Animal Unit of the 
University of Hong Kong according to the Associating for 
Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) international guidelines. The in vivo nude 
mouse tumorigenicity assay was conducted as previously 
described [14]. In brief, a total of 1 X 107 of HONE1 
and of HK1 cells were injected into athymic BALB/c 
Nu/Nu six to eight-week old nude mice subcutaneously. 
The tumor sizes were measured weekly. For the in vivo 
metastasis assay, intrasplenic injection in nude mice 
was utilized. A total of 1 X 106 of cells was injected into 
the spleen of the mouse. Metastasis of different tested 
experimental groups was monitored by intraperitoneal 
injection of D-Luciferin (150 mg/kg; StayBrite, Biovision) 
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into the mouse. The bioluminescent signal was detected 
using the Xenogen IVIS 100 in vivo Imaging System 
in the Faculty Core Facility, University of Hong Kong. 
After three weeks inoculation, the livers of the mice were 
excised and examined by a pathologist to assess liver 
metastasis frequency (no. mice showing liver metastasis/
no. mice in study group X 100%). The mouse livers were 
then paraffin embedded for further histological analysis.
huVec tube formation assay
The CM was prepared by adding serum-free media 
to the cells and after 16 hours of incubation, the CM for 
HUVEC tube formation assay was collected and the assay 
performed as previously described [38, 48]. The total tube 
length from at least three different fields was measured 
using SPOT software (Diagnostic Instrument). 
real-time quantitative rt-Pcr
Q-PCR was performed as previously described [14]. 
The IL6, IL8, VEGF165, and VEGF189 primers were 
designed as described [38, 47, 49].
real-time cell proliferation and invasion assays
The real-time cell proliferation and invasion 
assays were conducted using the E-plate and the CIM-
plate, respectively, with the xCelligence system (Roche) 
according to the manufacturer’s instructions and as 
previously described [50, 51].
VeGF elIsA analysis
The CM was prepared as described in previous 
section. CM was collected for investigation of the VEGF 
protein levels. The VEGF protein levels in the tested and 
control groups were measured by utilizing the Quantikine 
Human VEGF immunoassay system (R&D Systems) 
according to the manufacturer’s instructions as previously 
described [38, 48]. The absorbance was measured by the 
Labsystem Multiskan MS Plate Reader (Thermo Fisher 
Scientific).
Paraffin embedding and Hematoxylin and Eosin 
(h&e) staining
The paraffin embedding and H&E staining were 
performed as previously described [14]. 
statistical analysis
The results of in vitro assay represent the arithmetic 
mean + SD of determinations. Student’s t test was used to 
determine the confidence levels in group comparisons. The 
SEM was used to calculate the SE of the in vivo assay. The 
Fisher’s exact test was used to determine the confidence 
levels of the in vivo metastasis. A p-value <0.05 was 
considered statistically significant. 
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